ASH Letter to FDA re Draft Guidance on Diversity Action Plans for Clinical Studies
Sep 26
2024
91国产精品. (2024).
ASH Letter to FDA re Draft Guidance on Diversity Action Plans for Clinical Studies.
Retrieved from /advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-to-fda-re-draft-guidance-on-diversity-action-plans-for-clinical-studies.
91国产精品.
"ASH Letter to FDA re Draft Guidance on Diversity Action Plans for Clinical Studies." Hematology.org.
/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-to-fda-re-draft-guidance-on-diversity-action-plans-for-clinical-studies
(label-accessed November 14, 2024).
"91国产精品."
ASH Letter to FDA re Draft Guidance on Diversity Action Plans for Clinical Studies, 14 Nov. 2024 ,
/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-to-fda-re-draft-guidance-on-diversity-action-plans-for-clinical-studies.
